Ethylene Glycol

Ethylene Glycol

SCHEMBL3515847

O=C(OCCOC(=O)c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1.OCCO

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 6/20 0.88
ESR1 P03372 2/20 0.66
TYR P14679 3/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
AKR1C4 P17516 1/20 0.62
AKR1C3 P42330 1/20 0.62
AKR1C2 P52895 1/20 0.62
AKR1C1 Q04828 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2791373 0.94 SERPINE1 (1.00) SERPINE1ESR1TYRL3MBTL1AKR1C4
SCHEMBL1885404 0.92 SERPINE1 (0.81) SERPINE1ESR1TYRL3MBTL1AKR1C4
Ethylene SCHEMBL16144959 0.90 SERPINE1 (0.92) SERPINE1ESR1TYRL3MBTL1AKR1C4
Ethylene SCHEMBL16144978 0.90 SERPINE1 (0.92) SERPINE1ESR1TYRL3MBTL1AKR1C4
Ethylene SCHEMBL16144967 0.90 SERPINE1 (0.92) SERPINE1ESR1TYRL3MBTL1AKR1C4
Ethylene SCHEMBL16144936 0.90 SERPINE1 (0.92) SERPINE1ESR1TYRL3MBTL1AKR1C4
Ethylene SCHEMBL16144942 0.90 SERPINE1 (0.92) SERPINE1ESR1TYRL3MBTL1AKR1C4
Ethylene SCHEMBL16145015 0.90 SERPINE1 (0.92) SERPINE1ESR1TYRL3MBTL1AKR1C4
Ethylene SCHEMBL16144939 0.90 SERPINE1 (0.92) SERPINE1ESR1TYRL3MBTL1AKR1C4
Ethylene SCHEMBL16144984 0.90 SERPINE1 (0.92) SERPINE1ESR1TYRL3MBTL1AKR1C4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250138031-A1 IN VITRO MEASUREMENT OF THE LYSIS OF A FIBRIN CLOT DIAGNOSTICA STAGO (FR) 2025-05-01 US claimed
CN-118834553-A Preparation method of flash rust inhibitor 大连连昇新材料有限公司 2024-10-25 CN claimed
WO-2023041877-A1 IN VITRO MEASUREMENT OF THE LYSIS OF A FIBRIN CLOT DIAGNOSTICA STAGO (FR) 2023-03-23 WO claimed
US-7208266-B2 Endogenous coagulation activator compounds —use in exploring endogenous coagulation SOCIETE DIAGNOSTICA-STAGO (FR) 2007-04-24 US claimed
US-20030157582-A1 Endogenous coagulation activator compounds - use in exploring endogenous coagulation SOCIETE DIAGNOSTICA-STAGO (FR) 2003-08-21 US claimed
EP-1280758-A1 GALLIC ACID DERIVATIVES AND USE FOR EXPLORING ENDOGENETIC COAGULATION SOCIETE DIAGNOSTICA-STAGO (FR) 2003-02-05 EP claimed
WO-2002076921-A1 GALLIC ACID DERIVATIVES AND USE FOR EXPLORING ENDOGENETIC COAGULATION SOCIETE DIAGNOSTICA-STAGO (FR) 2002-10-03 WO claimed
US-20250138031-A1 IN VITRO MEASUREMENT OF THE LYSIS OF A FIBRIN CLOT DIAGNOSTICA STAGO (FR) 2025-05-01 US disclosed
CN-118834553-A Preparation method of flash rust inhibitor 大连连昇新材料有限公司 2024-10-25 CN disclosed
WO-2023041877-A1 IN VITRO MEASUREMENT OF THE LYSIS OF A FIBRIN CLOT DIAGNOSTICA STAGO (FR) 2023-03-23 WO disclosed
US-20100298403-A1 MODIFIED POLY(PROPYLENE-IMINE) DENDRIMERS AND THEIR USE AS TRANSFECTION AGENTS FOR AMIONIC BIOACTIVE FACTORS ( as amended JANSSEN PHARMACEUTICA N.V. (BE) 2010-11-25 US disclosed
EP-1904436-A1 MODIFIED POLY(PROPYLENE-IMINE) DENDRIMERS AND THEIR USE AS TRANSFECTION AGENTS FOR ANIONIC BIOACTIVE FACTORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-02 EP disclosed
US-7208266-B2 Endogenous coagulation activator compounds —use in exploring endogenous coagulation SOCIETE DIAGNOSTICA-STAGO (FR) 2007-04-24 US disclosed
WO-2007006700-A1 MODIFIED POLY(PROPYLENE-IMINE) DENDRIMERS AND THEIR USE AS TRANSFECTION AGENTS FOR ANIONIC BIOACTIVE FACTORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-18 WO disclosed
US-20030157582-A1 Endogenous coagulation activator compounds - use in exploring endogenous coagulation SOCIETE DIAGNOSTICA-STAGO (FR) 2003-08-21 US disclosed
EP-1280758-A1 GALLIC ACID DERIVATIVES AND USE FOR EXPLORING ENDOGENETIC COAGULATION SOCIETE DIAGNOSTICA-STAGO (FR) 2003-02-05 EP disclosed
WO-2002076921-A1 GALLIC ACID DERIVATIVES AND USE FOR EXPLORING ENDOGENETIC COAGULATION SOCIETE DIAGNOSTICA-STAGO (FR) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030157582-A1 Endogenous coagulation activator compounds - use in exploring endogenous coagulation TFPI, F2, F8 SERPINE1 20/4885ESR1 1071/4885TYR 3148/4885
US-20100298403-A1 MODIFIED POLY(PROPYLENE-IMINE) DENDRIMERS AND THEIR USE AS TRANSFECTION AGENTS FOR AMIONIC BIOACTIVE FACTORS ( as amended PAM, TIMM13, CYTH3 SERPINE1 3454/4885ESR1 618/4885TYR 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.